Commercially available assays for multiplex detection of alpha human papillomaviruses

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 10, 2010, Pages 1139-1162

  Poljak, Mario ^a   Kocjan, Botjan J ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

cervical cancer; diagnosis; HPV; human papillomaviruses; PCR

Indexed keywords

MESSENGER RNA; VIRUS DNA;

ALPHAPAPILLOMAVIRUS; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DNA DETERMINATION; GEL ELECTROPHORESIS; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 14; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE E6; HUMAN PAPILLOMAVIRUS TYPE E7; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MICROARRAY ANALYSIS; NONHUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE LINE BLOT HYBRIDIZATION; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SUSPENSION ARRAY; VALIDATION PROCESS; VIRUS CULTURE; VIRUS DETECTION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 77958163542     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.104     Document Type: Review

References (163)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401(1), 70-79 (2010). • Most recent Classification of papillomaviruses.
2. Burk RD. Nomenklatura. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3-8 July 2010.
3. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer DOI: 10.1002/ijc.25396 (2010) (Epub ahead of print).
4. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin. Otolaryngol. 31(4), 259-266 (2006).
5. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int. J. Cancer 124(7), 1626-1636 (2009).
6. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 20(4), 449-457 (2009).
7. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121(3), 621-632 (2007).
8. Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet. Gynecol. 113(4), 917-924 (2009).
9. Giuliano AR, Tortolero-Luna G, Ferrer E et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 26 (Suppl. 10), K17-K28 (2008).
10. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect. Agent Cancer 4, 8 (2009).
11. Wentzensen N, Schiffman M, Dunn T et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int. J. Cancer 125(9), 2151-2158 (2009).
12. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Impact of improved Classification on the association of human papillomavirus with cervical precancer. Am. J. Epidemiol. 171(2), 155-163 (2010).
13. Bouvard V, Baan R, Straif K et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol. 10(4), 321-322 (2009).
14. Muñoz N, Bosch FX, de Sanjosé S et al. Epidemiologic Classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348(6), 518-527 (2003). (Pubitemid 36159887)
15. Muñoz N, Bosch FX, Castellsagué X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111(2), 278-285 (2004).
16. Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. J. Clin. Virol. 32 (Suppl. 1), S43-S51 (2005).
17. Coutlée F, Mayrand MH, Roger M, Franco EL. Detection and typing of human papillomavirus nucleic acids in biological fluids. Public Health Genomics 12 (5-6), 308-318 (2009).
18. Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis. Markers 23(4), 273-281 (2007).
19. Snijders PJ, Heideman DA, Meijer CJ. Methods for HPV detection in exfoliated cell and tissue specimens. APMIS 118 (6-7), 520-528 (2010).
20. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6 (+) - mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol. 35(3), 791-795 (1997).
21. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 40(3), 779-787 (2002).
22. Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirusbased and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 (Suppl. 10), K29-K41 (2008). •• Excellent review of the use of human papillomavirus (HPV) testing in cervical screening.
23. Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119(5), 1095-1101 (2006).
24. Cox JT. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J. Clin. Virol. 45 (Suppl. 1), S3-S12 (2009). •• Excellent historical review of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results.
25. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. Validation of high-risk HPV tests for primary cervical screening. J. Clin. Virol. 46 (Suppl. 3), S1-S4 (2009).
26. Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124(3), 516-520 (2009). • Recommendation on how clinically to validate HPV assays to be used for primary cervical cancer screening.
27. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 (Suppl. 3), 78-89 (2006).
28. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening? Int. J. Cancer 125(11), 2489-2496 (2009).
29. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol. Oncol. 104(1), 232-246 (2007).
30. Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high risk cocktail. J. Clin. Virol. 25 (Suppl. 3), S89-S97 (2002).
31. Seme K, Fujs K, Kocjan BJ, Poljak M. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J. Virol. Methods 134 (1-2), 252-256 (2006).
32. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of Hybrid Capture 2. J. Clin. Microbiol. 46(8), 2595-2604 (2008).
33. Schutzbank TE, Jarvis C, Kahmann N, Lopez K, Weimer M, Yount A. Detection of high-risk papillomavirus DNA with commercial invader-technology-based analytespecific reagents following automated extraction of DNA from cervical brushings in ThinPrep media. J. Clin. Microbiol. 45(12), 4067-4069 (2007).
34. Wright TC Jr, Massad LS, Dunton CJ et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 197(4), 346-355 (2007).
35. Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ. Crosssectional comparison of an automated Hybrid Capture 2 assay and the consensus GP5+/6+ PCR method in a populationbased cervical screening program. J. Clin. Microbiol. 44(10), 3680-3685 (2006).
36. Poljak M, Kocjan BJ, Kovanda A et al. Human papillomavirus genotype specificity of hybrid capture 2 low-risk probe cocktail. J. Clin. Microbiol. 47(8), 2611-2615 (2009).
37. Szarewski A, Ambroisine L, Cadman L et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17(11), 3033-3042 (2008).
38. Sargent A, Bailey A, Turner A et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J. Clin. Microbiol. 48(2), 554-558 (2010).
39. Eder PS, Lou J, Huff J, Macioszek J. The next-generation Hybrid Capture High-Risk HPV DNA assay on a fully automated platform. J. Clin. Virol. 45 (Suppl. 1), S85-S92 (2009).
40. Day SP, Hudson A, Mast A et al. Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study. J. Clin. Virol. 45 (Suppl. 1), S63-S72 (2009).
41. Stillman MJ, Day SP, Schutzbank TE. A comparative review of laboratory-developed tests utilizing Invader HPV analyte-specific reagents for the detection of high-risk human papillomavirus. J. Clin. Virol. 45 (Suppl. 1), S73-S77 (2009).
42. Wong AK, Chan RC, Nichols WS, Bose S. Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay. J. Clin. Microbiol. 46(3), 869-875 (2008).
43. Ginocchio CC, Barth D, Zhang F. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA. J. Clin. Microbiol. 46(5), 1641-1646 (2008).
44. Harvey M, Stout S, Starkey CR, Hendren R, Holt S, Miller GC. The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection. J. Clin. Virol. 45 (Suppl. 1), S79-S83 (2009).
45. Johnson LR, Starkey CR, Palmer J et al. A comparison of two methods to determine the presence of high-risk HPV cervical infections. Am. J. Clin. Pathol. 130(3), 401-408 (2008).
46. Kurtycz DF, Smith M, He R, Miyazaki K, Shalkham J. Comparison of methods trial for high-risk HPV. Diagn. Cytopathol. 38(2), 104-108 (2010).
47. Einstein MH, Martens MG, Garcia FA et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol. Oncol. 118(2), 116-122 (2010).
48. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am. J. Clin. Pathol. 134(2), 193-199 (2010).
49. Poljak M, Fujs K, Seme K, Kocjan BJ, Vrtačnik-Bokal E. Retrospective and prospective evaluation of the Amplicor HPV test for detection of 13 high-risk human papillomavirus genotypes on 862 clinical samples. Acta Dermatovenerol. Alp. Pannon. Adriat. 14(4), 147-152 (2005).
50. van Ham MA, Bakkers JM, Harbers GK, Quint WG, Massuger LF, Melchers WJ. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J. Clin. Microbiol. 43(6), 2662-2667 (2005).
51. Sandri MT, Lentati P, Benini E et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol. 44(6), 2141-2146 (2006).
52. Stevens MP, Rudland E, Garland SM, Tabrizi SN. Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J. Clin. Microbiol. 44(7), 2428-2433 (2006).
53. Carozzi F, Bisanzi S, Sani C et al. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J. Clin. Microbiol. 45(2), 364-369 (2007).
54. Halfon P, Trepo E, Antoniotti G et al. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high risk HPV genotypes in atypical squamous cells of unceirtain significance. J. Clin. Microbiol. 45(2), 313-316 (2007).
55. Stevens MP, Garland SM, Rudland E, Tan J, Quinn MA, Tabrizi SN. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J. Clin. Microbiol. 45(7), 2130-2137 (2007).
56. Wahlström C, Iftner T, Dillner J, Dillner L; Swedescreen study group. Populationbased study of screening test performance indices of three human papillomavirus DNA tests. J. Med. Virol. 79(8), 1169-1175 (2007).
57. De Francesco MA, Gargiulo F, Schreiber C, Ciravolo G, Salinaro F, Manca N. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear. J. Virol. Methods 147(1), 10-17 (2008).
58. Mo LZ, Monnier-Benoit S, Kantelip B et al. Comparison of AMPLICOR and Hybrid Capture II assays for high-risk HPV detection in normal and abnormal liquied-based cytology: use of INNO-LiPA Genotyping assay to screeng the discordant results. J. Clin. Virol. 41(2), 104-110 (2008).
59. Wentzensen N, Gravitt PE, Solomon D, Wheeler CM, Castle PE. A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study. Cancer Epidemiol. Biomarkers Prev. 18(5), 1341-1349 (2009).
60. Monsonego J, Bohbot JM, Pollini G et al. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol. Oncol. 99(1), 160-168 (2005).
61. Grisaru D, Avidor B, Niv J et al. Pilot study of prevalence of high-risk human papillomavirus genotypes in Israeli Jewish women referred for colposcopic examination. J. Clin. Microbiol. 46(5), 1602-1605 (2008).
62. Koidl C, Bozic M, Hadzisejdic I et al. Comparison of molecular assays for detection and typing of human papillomavirus. Am. J. Obstet. Gynecol. 199(2), 144.e1-6 (2008).
63. Gravitt PE, Coutlée F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine. 26 Suppl. 10), K42-K52 (2008). •• Excellent review of the new technologies in cervical cancer screening.
64. Qiao YL, Sellors JW, Eder PS et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 9(10), 929-936 (2008). • Important study that showed the usefulness of the new rapid and simple HPV test as a primary screening method for the prevention of cervical cancer in low-resource countries.
65. Schlecht NF, Kulaga S, Robitaille J et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286(24), 3106-3114 (2001).
66. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst. 97(14), 1072-1079 (2005). •• Landmark study that showed the exceptionally high oncogenic potential of HPV-16 and HPV-18 compared with other high-risk-HPV types.
67. Huang S, Tang N, Mak WB et al. Principles and analytical performance of Abbott RealTime HR HPV test. J. Clin. Virol. 45 (Suppl. 1), S13-S17 (2009).
68. Poljak M, Kovanda A, Kocjan BJ, Seme K, Jancar N, Vrtacnik-Bokal E. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatovenerol. Alp. Panonica Adriat. 18(3), 94-103 (2009).
69. Tang N, Huang S, Erickson B et al. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. J. Clin. Virol. 45 (Suppl. 1), S25-S29 (2009).
70. Huang S, Erickson B, Tang N et al. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J. Clin. Virol. 45 (Suppl. 1), S19-S23 (2009).
71. Kaliterna V, Lepej SZ, Vince A. Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens. J. Med. Microbiol. 58(12), 1662-1663 (2009).
72. Cuzick J, Ambroisine L, Cadman L et al. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J. Med. Virol. 82(7), 1186-1191 (2010).
73. Halfon P, Benmoura D, Agostini A et al. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. J. Clin. Virol. 48(4), 246-250 (2010).
74. Castle PE, Sadorra M, Lau T, Aldrich C, Garcia FA, Kornegay J. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J. Clin. Microbiol. 47(10), 3344-3347 (2009).
75. Wright T Jr, Sharma A, Gutekunst K et al. High Risk for >CIN2 in cobas4800 HPV 16/18 positive women >30 yrs with NILM cytology: ATHENA results. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3-8 July 2010.
76. Stoler M, Sharma A, Gutekunst K et al. Cobas 4800 HPV Test Performance for >CIN2 and >CIN3 detection in women with ASC-US: ATHENA results. Presented at: 26th International Papillomavirus C onference. Montreal, Canada, 3-8 July 2010.
77. Lepej SZ, Grgić I, Poljak M et al. Detection of human papillomavirus genotypes 16/18/45 by hybrid capture hybridisation genotyping probe in clinical specimens: the first report. J. Clin. Virol. 40(2), 171-172 (2007).
78. Tiews S, Steinberg W, Schneider W, Hanrath C. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data. J. Clin. Virol. 46 (Suppl. 3), S11-S15 (2009).
79. Hantz S, Decroisette E, Caly H et al. Testing of a new probe 16/18/45 Hybrid Capture (Digene) in women with high risk HPV infection. Pathol. Biol. (Paris) 57(1), 81-85 (2009).
80. Thai H, Rangwala S, Gay T et al. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology. J. Clin. Virol. 45 (Suppl. 1), S93-S97 (2009).
81. Vince A, Lepej SZ. Diagnostic methods and techniques in cervical cancer prevention Part II: molecular diagnostics of HPV infection. Med. Glas. Ljek. komore Zenicko-doboj kantona 7(1), 18-25 (2010).
82. van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J. Clin. Microbiol. 44(9), 3122-3129 (2006).
83. Feng Q, Cherne S, Winer RL et al. Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses. J. Clin. Microbiol. 47(3), 547-553 (2009).
84. Kleter B, van Doorn LJ, Schrauwen L et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37(8), 2508-2517 (1999).
85. Hesselink AT, van Ham MA, Heideman DA et al. Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J. Clin. Microbiol. 46(10), 3215-3221 (2008).
86. Castle PE, Porras C, Quint WG et al. Comparison of two PCR-based human papillomavirus genotyping methods. J. Clin. Microbiol. 46(10), 3437-3445 (2008).
87. Didelot-Rousseau MN, Courgnaud V, Nagot N et al. Comparison of INNO-LiPA HPV Genotyping v2 with PCR product subcloning and sequencing for identification of genital human papillomavirus genotypes in African women. J. Virol. Methods 135(2), 181-185 (2006).
88. Iftner T, Germ L, Swoyer R et al. Study comparing human papillomavirus (HPV) real-time multiplex PCR and Hybrid Capture II INNO-LiPA v2 HPV genotyping PCR assays. J. Clin. Microbiol. 47(7), 2106-2113 (2009).
89. Seme K, Lepej SZ, Lunar MM et al. Digene HPV Genotyping RH Test RUO: comparative evaluation with INNO-LiPA HPV Genotyping Extra Test for detection of 18 high-risk and probable high-risk human papillomavirus genotypes. J. Clin. Virol. 46(2), 176-179 (2009).
90. Gravitt PE, Peyton CL, Alessi TQ et al. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38(1), 357-361 (2000).
91. Greer CE, Wheeler CM, Manos MM. Sample preparation and PCR amplification from paraffin-embedded tissues. PCR Methods Appl. 3(6), S113-S122 (1994).
92. Coutlée F, Rouleau D, Ghattas G et al. Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J. Clin. Microbiol. 45(11), 3821-3823 (2007).
93. Marks M, Gupta SB, Liaw KL et al. Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array using HPV52-specific TaqMan E6/E7 quantitative real-time PCR. J. Virol. Methods 156 (1-2), 152-156 (2009).
94. Stevens MP, Garland SM, Tabrizi SN. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J. Virol. Methods 147(2), 290-296 (2008).
95. Kocjan BJ, Poljak M, Seme K. Universal ProbeLibrary based real-time PCR assay for detection and confrmation of human papillomavirus genotype 52 infections. J. Virol. Methods 163(2), 492-494 (2010).
96. Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J. Virol. Methods 156 (1-2), 77-83 (2009).
97. Halfon P, Benmoura D, Khiri H et al. Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay. J. Clin. Virol. 47(1), 38-42 (2010).
98. Schopp B, Holz B, Zago M et al. Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. J. Med. Virol. 82(4), 605-615 (2010).
99. Galan-Sanchez F, Rodriguez-Iglesias MA. Comparison of human papillomavirus genotyping using commercial assays based on PCR and reverse hybridization methods. APMIS 117(10), 708-715 (2009).
100. Liu SS, Leung RC, Chan KK, Cheung AN, Ngan HY. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. J. Clin. Microbiol. 48(3), 758-764 (2010).
101. Halfon P, Benmoura D, Agostini A et al. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J. Clin. Virol. 47(2), 177-181 (2010).
102. Geraets DT, Heideman DA, de Koning MN et al. High genotyping concordance between the digene HPV genotyping RH test and the reverse line blot genotyping assay on GP5+/6+-PCR products. J. Clin. Virol. 46 (Suppl. 3), S16-S20 (2009).
103. Huang HJ, Huang SL, Lin CY et al. Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int. J. Gynecol. Cancer 14(4), 639-649 (2004).
104. Huang SL, Chao A, Hsueh S et al. Comparison between the Hybrid Capture II Test and an SPF1/GP6+ PCR-based assay for detection of human papillomavirus DNA in cervical swab samples. J. Clin. Microbiol. 44(5), 1733-1739 (2006).
105. Lin CY, Chen HC, Lin RW et al. Quality assurance of genotyping array for detection and typing of human papillomavirus. J. Virol. Methods 140 (1-2), 1-9 (2007).
106. Lin CY, Chao A, Yang YC et al. Human papillomavirus typing with a polymerase chain reaction-based genotyping array compared with type-specific PCR. J. Clin. Virol. 42(4), 361-367 (2008).
107. Lai CH, Huang HJ, Hsueh S et al. Human papillomavirus genotype in cervical cancer: a population-based study. Int. J. Cancer 120(9), 1999-2006 (2007).
108. Chao A, Chang CJ, Lai CH et al. Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology - a population-based cohort study from Taiwan. Int. J. Cancer 126(1), 191-198 (2010).
109. Hesselink AT, Heideman DA, Berkhof J et al. Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening. J. Clin. Microbiol. 48(3), 797-801 (2010).
110. Jones J, Powell NG, Tristram A, Fiander AN, Hibbitts S. Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set. J. Clin. Virol. 45(2), 100-104 (2009).
111. García-Sierra N, Martró E, Castellà E et al. Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening. J. Clin. Microbiol. 47(7), 2165-2169 (2009).
112. Gomez-Roman JJ, Echevarria C, Salas S et al. A type-specific study of human papillomavirus prevalence in cervicovaginal samples in three different Spanish regions. APMIS 117(1), 22-27 (2009).
113. Sun ZR, Ji YH, Zhou WQ, Zhang SL, Jiang WG, Ruan Q. Characteristics of HPV prevalence among women in Liaoning province, China. Int. J. Gynaecol. Obstet. 109(2), 105-109 (2010).
114. Lin M, Yang LY, Li LJ, Wu JR, Peng YP, Luo ZY. Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust. NZ J. Obstet. Gynaecol. 48(2), 189-194 (2008).
115. Oh TJ, Kim CJ, Woo SK et al. Development and clinical evaluation of a highly sensitive DNA microarray for detection and genotyping of human papillomaviruses. J. Clin. Microbiol. 42(7), 3272-3280 (2004).
116. Erali M, Pattison DC, Wittwer CT, Petti CA. Human papillomavirus genotyping using an automated flm-based chip array. J. Mol. Diagn. 11(5), 439-445 (2009).
117. Choi JJ, Kim C, Park H. Peptide nucleic acid-based array for detecting and genotyping human papillomaviruses. J. Clin. Microbiol. 47(6), 1785-1790 (2009).
118. Klug SJ, Molijn A, Schopp B et al. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J. Med. Virol. 80(7), 1264-1274 (2008).
119. Hwang HS, Park M, Lee SY, Kwon KH, Pang MG. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2, 470 Korean women determined by DNA chip. Cancer Epidemiol. Biomarkers Prev. 13(12), 2153-2156 (2004).
120. Kim KH, Yoon MS, Na YJ, Park CS, Oh MR, Moon WC. Development and evaluation of a highly sensitive human papillomavirus genotyping DNA chip. Gynecol. Oncol. 100(1), 38-43 (2006).
121. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J. Clin. Microbiol. 44(2), 504-512 (2006).
122. Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J. Clin. Microbiol. 46(3), 1050-1059 (2008).
123. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J. Clin. Microbiol. 48(1), 143-149 (2010).
124. Oh Y, Bae SM, Kim YW et al. Polymerase chain reaction-based fuorescent Luminex assay to detect the presence of human papillomavirus types. Cancer Sci. 98(4), 549-554 (2007).
125. Jiang HL, Zhu HH, Zhou LF, Chen F, Chen Z. Genotyping of human papillomavirus in cervical lesions by L1 consensus PCR and the Luminex xMAP system. J. Med. Microbiol. 55 (Pt 6), 715-720 (2006).
126. Nazarenko I, Kobayashi L, Giles J, Fishman C, Chen G, Lorincz A. A novel method of HPV genotyping using Hybrid Capture sample preparation method combined with GP5+/6+ PCR and multiplex detection on Luminex XMAP. J. Virol. Methods 154 (1-2), 76-81 (2008).
127. Wallace J, Woda BA, Pihan G. Facile, comprehensive, high-throughput genotyping of human genital papillomaviruses using spectrally addressable liquid bead microarrays. J. Mol. Diagn. 7(1), 72-80 (2005).
128. Geraets DT, Heideman DA, de Koning MN et al. High-throughput genotyping of high-risk HPV by the Digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology. J. Clin. Virol. 46 (Suppl. 3), S21-S26 (2009).
129. Mammas IN, Sourvinos G, Vakonaki E, Giamarelou P, Michael C, Spandidos DA. Novel human papilloma virus (HPV) genotypes in children with recurrent respiratory papillomatosis. Eur. J. Pediatr. 169(8), 1017-1021 (2010).
130. Lie AK, Kristensen G. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev. Mol. Diagn. 8(4), 405-415 (2008).
131. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 17(10), 2536-2545 (2008).
132. Molden T, Kraus I, Skomedal H, Nordstrøm T, Karlsen F. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J. Virol. Methods 142 (1-2), 204-212 (2007).
133. Lie AK, Risberg B, Borge B et al. DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol. Oncol. 97(3), 908-915 (2005).
134. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J. Med. Virol. 73(1), 65-70 (2004).
135. Keegan H, Mc Inerney J, Pilkington L et al. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J. Virol. Methods 155(1), 61-66 (2009).
136. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4, 136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol. Biomarkers Prev. 14(2), 367-372 (2005).
137. Molden T, Nygard JF, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer 114(6), 973-976 (2005).
138. Tropé A, Sjøborg K, Eskild A et al. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J. Clin. Microbiol. 47(8), 2458-2464 (2009).
139. Dockter J, Schroder A, Eaton B et al. Analytical characterization of the APTIMA HPV Assay. J. Clin. Virol. 45 (Suppl. 1), S39-S47 (2009).
140. Jeantet D, Schwarzmann F, Tromp J et al. NucliSENS EasyQ HPV v1 test-testing for oncogenic activity of human papillomaviruses. J. Clin. Virol. 45 (Suppl. 1), S29-S37 (2009).
141. Boulet GA, Micalessi IM, Horvath CA, Benoy IH, Depuydt CE, Bogers JJ. Nucleic acid-sequence based amplification assay for HPV mRNA detection and typing: evidence for DNA amplification. J. Clin. Microbiol. 48(7), 2524-2529 (2010).
142. Getman D, Aiyer A, Dockter J, Giachetti C, Zhang F, Ginocchio CC. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets. J. Clin. Virol. 45 (Suppl. 1), S49-S54 (2009).
143. Castle PE, Dockter J, Giachetti C et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin. Cancer Res. 13(9), 2599-2605 (2007).
144. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J. Clin. Virol. 45 (Suppl. 1), S55-S61 (2009).
145. Cuschieri K, Kitchener H, Horne A et al. Clinical performance of a broad-spectrum RNA assay in a high-prevalence disease setting. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3-8 July 2010.
146. Monsonego J, Hugens M, Zerat L et al. Comparison of the APTIM A HPV mRNA Assay with the Hybrid Capture 2 HPV DNA Assay and cytology in cervical cancer screening. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3-8 July 2010. • First study to show equal clinical sensitivity but higher clinical specificity for CIN2+/CIN3+ of an mRNA-based assay in
147. Guo M, Gong Y, Deavers M et al. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J. Clin. Microbiol. 46(1), 274-280 (2008).
148. Kong CS, Balzer BL, Troxell ML, Patterson BK, Longacre TA. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am. J. Surg. Pathol. 31(1), 33-43 (2007).
149. Mirasoli M, Guardigli M, Simoni P et al. Multiplex chemiluminescence microscope imaging of P16 (INK4A) and HPV DNA as biomarker of cervical neoplasia. Anal Bioanal. Chem. 394(4), 981-987 (2009).
150. Narimatsu R, Patterson BK. Highthroughput cervical cancer screening using intracellular human papillomavirus E6 and E7 mRNA quantification by flow cytometry. Am. J. Clin. Pathol. 123(5), 716-723 (2005).
151. Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J. Clin. Virol. 32 (Suppl. 1), S34-S42 (2005).
152. Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am. J. Clin. Pathol. 127(3), 335-337 (2007). • Recommendation on how clinically to validate HPV assays to be used for primary cervical cancer screening.
153. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev. Mol. Diagn. 8(5), 599-605 (2008).
154. Grce M. Primary and secondary prevention of cervical cancer. Expert Rev. Mol. Diagn. 9(8), 851-857 (2009).
155. Castle PE, Rodríguez AC, Burk RD et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. Br. Med. J. 339, b2569 (2009).
156. Arbyn M, Cuzick J. International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention. Cancer Lett. 278(1), 1-2 (2009).
157. Wilkinson DE, Baylis SA, Padley D et al. Establishment of the 1st WHO international standards for human papillomavirus type 16 DNA and type 18 DNA. Int. J. Cancer 126(12), 2969-2983 (2010).
158. Gök M, Heideman DA, van Kemenade FJ et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. Br. Med. J. 340: c1040 (2010).
159. Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360(14), 1385-1394 (2009).
160. Schiffman M, Rodriguez AC, Chen Z et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res. 70(8), 3159-3169 (2010).
161. Castle PE. New molecular markers for cervical cancer screening: distinguishing hype from hope. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3-8 July 2010.
162. McCredie MR, Sharples KJ, Paul C et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9(5), 425-434 (2008).
163. Bosch FH. Editorial: The transition time for screening programs. HPV Today 20, 2 (2010).